Latest Share Purchase Plans News

Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.

Andean Silver has delivered robust drilling results at Cerro Bayo, reinforcing resource continuity and growth prospects ahead of a June mineral resource update and ongoing restart studies.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Brightstar Resources (ASX:BTR) has fully funded its Goldfields Project development with a $193 million equity raise and a US$120 million senior secured bond, targeting 75,000oz gold production from mid-2027 while progressing Sandstone towards a Final Investment Decision.

Arafura Rare Earths has locked in binding cornerstone equity agreements worth approximately A$230 million, bolstering its path to a final investment decision for the Nolans Project. The company also acquired critical camp infrastructure and is progressing technology development and offtake negotiations amid supportive government frameworks.

Maritana Minerals has confirmed robust economics and high-grade drilling results at its Black Swan gold project near Kalgoorlie, backed by a $175 million capital raise and a $35 million asset divestment.

HighCom Technology secures a nearly A$10 million contract from the Australian Defence for counter small uncrewed aerial systems, marking its first major C-UAS order and reinforcing its defence sector presence.

DevEx Resources is gearing up for a major uranium drilling campaign in 2026 after expanding its Northern Territory footprint and securing nearly $39 million in fresh capital. Soil anomalies at Murphy West and strategic licence acquisitions set the stage for exploration in the McArthur Basin.

Santana Minerals advanced its Bendigo-Ophir Gold Project in New Zealand with a confirmed consent decision date, major equipment agreements, and a substantial capital raise, setting the stage for development.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

Beetaloo Energy has launched a $5 million Share Purchase Plan at $0.28 per share, following a $66.3 million institutional placement at the same price. The SPP aims to fund ongoing development activities ahead of first gas production in late 2026.

Fat Prophets Global Contrarian Fund (ASX: FPC) is raising up to $8.45 million through a pro-rata rights issue priced at a premium, offering one option per new share. The issue is partly underwritten and sees directors committing to full participation.